Jalleh RJ, Rayner CK, Hausken T, Jones KL, Camilleri M, Horowitz M
Billiauws L, Joly F
[DOI] [PMC free article] [PubMed] [Google Scholar] 14.Thomas CE, Mauer EA, Shukla AP, et al
Eli Lilly and Company, and Novo Nordisk are key players in GLP-1 agonists market
Specifically, these drugs: Increase insulin production, which lowers blood sugar Delay digestion in the stomach, reducing hunger levels Send signals to the brain indicating that a person has eaten enough and feels full Promote the breakdown of cholesterol in the bloodstream, reducing a persons heart risk Lower blood pressure by inhibiting inflammation in the blood vessels Reduce blood sugar production in the liver, protecting the organ from potential scarring All these emerging benefits have made GLP-1 RAs an important pharmacological drug, concluded the research team led by senior researcher Dr